NASDAQ:PTGX

Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

$17.57

+0.08 (+0.46%)

(As of 09/27/2023 ET)

Compare

Today's Range: $17.24
▼
$17.78
50-Day Range: $16.98
▼
$20.37
52-Week Range: $7.24
▼
$30.10

Volume: 406,299 shs
Average Volume: 648,547 shs
Market Capitalization: $1.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.00

Protagonist Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 110.6% Upside
$37.00 Price Target
Short Interest: Healthy
4.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.01
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.35) to ($2.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

631st out of 976 stocks

Pharmaceutical Preparations Industry

301st out of 455 stocks

3.5

Analyst's Opinion

Consensus Rating
Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.00, Protagonist Therapeutics has a forecasted upside of 110.6% from its current price of $17.57.
Amount of Analyst Coverage
Protagonist Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.87% of the outstanding shares of Protagonist Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Protagonist Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Protagonist Therapeutics has recently increased by 1.82%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Protagonist Therapeutics does not currently pay a dividend.
Dividend Growth
Protagonist Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTGX.

1.7

News and Social Media Coverage

News Sentiment
Protagonist Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Protagonist Therapeutics this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Protagonist Therapeutics is held by insiders.
Percentage Held by Institutions
98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.35) to ($2.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Protagonist Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Protagonist Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Protagonist Therapeutics has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX Price History

30 days | 90 days | 365 days | Advanced Chart

PTGX Stock News Headlines

September 26, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Cut to $34.00 by Analysts at JPMorgan Chase & Co.

September 26, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 3.9% on Analyst Downgrade

September 28, 2023 | MarketBeat Internal (Ad)

30 Days of MarketBeat All Access Free

Access our premier stock research platform that includes research tools, stock screeners, instant alerts, real-time news and much more.

September 26, 2023 | msn.com

JP Morgan Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation

September 24, 2023 | americanbankingnews.com

Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at StockNews.com

September 5, 2023 | finance.yahoo.com

Protagonist Therapeutics to Present at Upcoming Investor Conferences

August 9, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Receives $34 Million from Warrant Exercises

August 9, 2023 | finance.yahoo.com

Protagonist Receives $34 Million from Warrant Exercises

September 28, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 4, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), Dynavax (DVAX)

August 3, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 3, 2023 | finance.yahoo.com

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 22, 2023 | finance.yahoo.com

PTGX - Protagonist Therapeutics, Inc.

July 18, 2023 | finanznachrichten.de

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Reports Granting of Inducement Award

July 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and KalVista Pharmaceuticals (KALV)

July 6, 2023 | msn.com

JMP Securities Maintains Protagonist Therapeutics (PTGX) Market Outperform Recommendation

July 6, 2023 | msn.com

Expert Ratings for Protagonist Therapeutics

July 6, 2023 | markets.businessinsider.com

Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive

July 5, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

July 5, 2023 | finance.yahoo.com

Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment

July 4, 2023 | msn.com

Piper Sandler Reiterates Protagonist Therapeutics (PTGX) Overweight Recommendation

July 4, 2023 | msn.com

BTIG Reiterates Protagonist Therapeutics (PTGX) Buy Recommendation

July 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Protagonist Therapeutics (PTGX) and Arcus Biosciences (RCUS)

July 4, 2023 | finance.yahoo.com

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

July 3, 2023 | fool.com

Protagonist Therapeutics (NASDAQ: PTGX)

July 3, 2023 | benzinga.com

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday

June 30, 2023 | finance.yahoo.com

Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why

See More Headlines

Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Company Calendar

Last Earnings: 8/03/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PTGX
CUSIP: N/A
CIK: 1377121
Web: www.protagonist-inc.com
Phone: (510) 474-0170
Fax: N/A
Employees: 106
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.00
High Stock Price Forecast: $41.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +110.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-127,390,000.00
Net Margins: N/A
Pretax Margin: -16,319.91%
Return on Equity: -56.78%
Return on Assets: -50.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.01
Quick Ratio: 12.01

Sales & Book Value

Annual Sales: $26.58 million
Price / Sales: 38.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.38 per share
Price / Book: 4.01

Miscellaneous

Outstanding Shares: 57,530,000
Free Float: 54,654,000
Market Cap: $1.01 billion
Optionable: Not Optionable
Beta: 1.86

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Dinesh V. Patel Ph.D. (Age 66)
CEO, Pres, Sec. & Director
Comp: $883.46k

Dr. Suneel K. Gupta Ph.D. (Age 65)
Chief Devel. Officer
Comp: $640.89k

Dr. Mark Smythe Ph.D. (Age 58)
Founder & VP Technology

Mr. Asif Ali (Age 49)
Exec. VP & Chief Financial Officer

Mr. Mohammad Masjedizadeh Ph.D.
Exec. VP & Chief Technical Officer

Mr. Matthew M. Gosling (Age 52)
Exec. VP & Gen. Counsel

Ms. Carena Spivey
Sr. VP of HR

Dr. Ashok Bhandari Ph.D. (Age 59)
Exec. VP & Chief Drug Discovery and Preclinical Devel. Officer

Dr. Scott Eric Plevy M.D.
Exec. VP & Therapeutic Head of Gastroenterology

Mr. Carter J. King (Age 52)
Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PTGX Stock - Frequently Asked Questions

Should I buy or sell Protagonist Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares.
View PTGX analyst ratings or view top-rated stocks.
What is Protagonist Therapeutics' stock price forecast for 2023?: 3 Wall Street research analysts have issued 1-year target prices for Protagonist Therapeutics' stock. Their PTGX share price forecasts range from $34.00 to $41.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 110.6% from the stock's current price.
View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.
How have PTGX shares performed in 2023?: Protagonist Therapeutics' stock was trading at $10.91 on January 1st, 2023. Since then, PTGX shares have increased by 61.0% and is now trading at $17.57.
View the best growth stocks for 2023 here.
When is Protagonist Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PTGX earnings forecast.
How were Protagonist Therapeutics' earnings last quarter?: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03.
What ETF holds Protagonist Therapeutics' stock ?: Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio.
What other stocks do shareholders of Protagonist Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?: (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.
What is Protagonist Therapeutics' stock symbol?: Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."
Who are Protagonist Therapeutics' major shareholders?: Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.71%), State Street Corp (6.17%), Cowen AND Company LLC (2.90%), Cormorant Asset Management LP (2.61%), Perceptive Advisors LLC (2.55%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends.
How do I buy shares of Protagonist Therapeutics?: Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Protagonist Therapeutics' stock price today?: One share of PTGX stock can currently be purchased for approximately $17.57.
How much money does Protagonist Therapeutics make?: Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.01 billion and generates $26.58 million in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.
How many employees does Protagonist Therapeutics have?: The company employs 106 workers across the globe.
How can I contact Protagonist Therapeutics?: Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com.

This page (NASDAQ:PTGX) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial